Board Member
Aurinia Pharmaceuticals Inc. (AUPH)Equibles does not estimate personal net worth.
Get an email with a short summary when Aurinia Pharmaceuticals Inc. publishes a filing, an earnings call transcript or a press release.
Get AUPH alertsPeter Greenleaf is recorded as Board Member at Aurinia Pharmaceuticals Inc. (AUPH) since May 15, 2025 and CEO at Aurinia Pharmaceuticals Inc. (AUPH). The newest filing on record that lists Peter Greenleaf as CEO and Board Member at Aurinia Pharmaceuticals Inc. (AUPH) is dated April 21, 2026. Aurinia Pharmaceuticals Inc. reported in an 8-K filed March 23, 2026 that Peter Greenleaf resigned as Director, effective March 21, 2026. Aurinia Pharmaceuticals Inc. reported in an 8-K filed May 15, 2025 that Peter Greenleaf was appointed members of the Company's board of directors, effective May 15, 2025. The proxy statement of Aurinia Pharmaceuticals Inc. reports total compensation of $5,858,590 for Peter Greenleaf in fiscal 2025, including a base salary of $822,877. Disclosed compensation is on record for 8 fiscal years. Peter Greenleaf has spoken on 23 earnings calls across 1 company, most recently for Aurinia Pharmaceuticals Inc. on February 26, 2026. Aurinia Pharmaceuticals Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Aurinia Pharmaceuticals Inc. includes Jeffrey Bailey (CEO and Board Member), Kevin Tang (CEO and Board Member), Joseph Miller (CFO) and 7 others.
“Mr. Greenleaf resigned from the Board of Directors of Aurinia effective March 21, 2026.”
“the shareholders elected Mr. Kevin Tang, Mr. Jeffrey A. Bailey, Ms. Kathy L. Goetz, Mr. Peter Greenleaf, Mr. Craig Johnson and Ms. Tina S. Nova to serve as members of the Company's board of directors until the annual general meeting of shareholders to be held in 2026.”
“We want to thank you all for joining us today to discuss Arrhenia's fourth quarter and full year 2025 update. Joining me on the call today are Joe Miller, our Chief Financial Officer, and Dr. Greg Keenan, our Chief Medical Officer.”
“Joining me on the call today are Joe Miller, our Chief Financial Officer; and Dr. Greg Keenan, our Chief Medical Officer. Before we begin our discussion, I'd like to direct your attention to Slide 2, which contains important information regarding forward-looking statements.”
“I want to thank everybody for joining us today. On this morning's call, I'll provide an update on our second quarter results and provide an update on all corporate initiatives.”
“I want to thank everybody for joining us today. On this morning's call, I'll provide an update on our first quarter 2025 results and provide an update on recent progress.”
“I want to thank everybody for joining us on the call today. On this morning's call, I'll provide the details on our third quarter business metrics and how we are preparing for the rest of the year.”
2025-05-15–present
Last confirmed April 21, 2026
Start not stated–present
Last confirmed April 21, 2026
2025-05-15–2026-03-21
Start not stated–2026-03-21
Biotechnology · Healthcare
CEO, Board Member
2025-05-15–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Aurinia Pharmaceuticals Inc. (AUPH) | Former Chief Executive Officer | $822,877 | $5,858,590 |
| 2024 | Aurinia Pharmaceuticals Inc. (AUPH) | Chief Executive Officer | $822,877 | $6,417,897 |
| 2023 | Aurinia Pharmaceuticals Inc. (AUPH) | Chief Executive Officer | $822,877 | $10,573,359 |
| 2022 | Aurinia Pharmaceuticals Inc. (AUPH) | Chief Executive Officer | $791,228 | $8,837,397 |
| 2021 | Aurinia Pharmaceuticals Inc. (AUPH) | Chief Executive Officer | $723,905 | $1,240,821 |
| 2020 | Aurinia Pharmaceuticals Inc. (AUPH) | Chief Executive Officer | $673,400 | $10,679,282 |
| 2019 | Aurinia Pharmaceuticals Inc. (AUPH) | Chief Executive Officer | $438,258 | $5,236,630 |
| 2018 | Aurinia Pharmaceuticals Inc. (AUPH) | Chief Executive Officer | — | — |
